Greenleaf Trust Lowers Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Greenleaf Trust trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,173 shares of the medical research company’s stock after selling 113 shares during the quarter. Greenleaf Trust’s holdings in IQVIA were worth $624,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of IQV. Private Trust Co. NA increased its holdings in shares of IQVIA by 10.7% in the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the period. Clear Harbor Asset Management LLC increased its holdings in shares of IQVIA by 1.3% in the third quarter. Clear Harbor Asset Management LLC now owns 3,969 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 50 shares during the period. Pine Valley Investments Ltd Liability Co grew its holdings in IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares during the period. Fortitude Family Office LLC grew its holdings in IQVIA by 2.9% during the third quarter. Fortitude Family Office LLC now owns 1,977 shares of the medical research company’s stock worth $468,000 after acquiring an additional 56 shares during the period. Finally, Huntington National Bank grew its holdings in IQVIA by 7.4% during the third quarter. Huntington National Bank now owns 809 shares of the medical research company’s stock worth $192,000 after acquiring an additional 56 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on IQV. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Robert W. Baird dropped their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Truist Financial dropped their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, TD Cowen decreased their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $254.53.

IQVIA Stock Performance

NYSE IQV opened at $200.00 on Wednesday. The business’s 50-day moving average price is $200.31 and its 200 day moving average price is $220.14. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73. The company has a market capitalization of $36.30 billion, a PE ratio of 26.25, a price-to-earnings-growth ratio of 2.15 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.